TFF Pharmaceuticals, Inc. (NASDAQ:TFFP – Get Rating) insider Zamaneh Mikhak purchased 15,000 shares of TFF Pharmaceuticals stock in a transaction that occurred on Friday, March 10th. The stock was acquired at an average cost of $0.82 per share, with a total value of $12,300.00. Following the transaction, the insider now owns 15,000 shares in the company, valued at approximately $12,300. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
TFF Pharmaceuticals Trading Up 8.0 %
NASDAQ TFFP opened at $0.78 on Tuesday. The company has a fifty day simple moving average of $0.90 and a 200 day simple moving average of $2.11. TFF Pharmaceuticals, Inc. has a 12-month low of $0.62 and a 12-month high of $7.70. The company has a market cap of $27.15 million, a P/E ratio of -0.57 and a beta of 1.21.
Institutional Trading of TFF Pharmaceuticals
Several hedge funds have recently bought and sold shares of the business. AIGH Capital Management LLC acquired a new stake in TFF Pharmaceuticals in the 4th quarter valued at $1,826,000. DRW Securities LLC acquired a new stake in TFF Pharmaceuticals in the 4th quarter valued at $1,050,000. Millennium Management LLC acquired a new stake in TFF Pharmaceuticals in the 4th quarter valued at $200,000. Two Sigma Investments LP purchased a new position in TFF Pharmaceuticals during the 4th quarter worth $60,000. Finally, Renaissance Technologies LLC purchased a new position in TFF Pharmaceuticals during the 4th quarter worth $76,000. Institutional investors and hedge funds own 16.46% of the company’s stock.
TFF Pharmaceuticals Company Profile
TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
- Get a free copy of the StockNews.com research report on TFF Pharmaceuticals (TFFP)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.